Wall Street brokerages expect Genomic Health, Inc. (NASDAQ:GHDX) to report earnings of $0.07 per share for the current quarter, according to Zacks Investment Research. Six analysts have made estimates for Genomic Health’s earnings, with the lowest EPS estimate coming in at $0.05 and the highest estimate coming in at $0.10. Genomic Health posted earnings of $0.03 per share in the same quarter last year, which indicates a positive year over year growth rate of 133.3%. The company is scheduled to announce its next quarterly earnings report on Wednesday, November 14th.

According to Zacks, analysts expect that Genomic Health will report full year earnings of $0.56 per share for the current financial year, with EPS estimates ranging from $0.46 to $0.69. For the next financial year, analysts forecast that the firm will report earnings of $0.77 per share, with EPS estimates ranging from $0.47 to $0.95. Zacks Investment Research’s EPS calculations are an average based on a survey of research firms that that provide coverage for Genomic Health.

Genomic Health (NASDAQ:GHDX) last issued its earnings results on Thursday, August 2nd. The medical research company reported $0.26 EPS for the quarter, beating the consensus estimate of $0.07 by $0.19. The company had revenue of $95.60 million during the quarter, compared to analysts’ expectations of $92.23 million. Genomic Health had a net margin of 1.18% and a return on equity of 9.09%. The business’s revenue for the quarter was up 14.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($0.08) EPS.

Several equities analysts have recently issued reports on GHDX shares. Piper Jaffray Companies reissued a “hold” rating and issued a $60.00 price target on shares of Genomic Health in a report on Friday, August 3rd. Jefferies Financial Group reissued a “hold” rating and issued a $50.00 price target on shares of Genomic Health in a report on Friday, August 3rd. Zacks Investment Research lowered shares of Genomic Health from a “buy” rating to a “hold” rating in a report on Tuesday, August 7th. ValuEngine raised shares of Genomic Health from a “hold” rating to a “buy” rating in a report on Friday, May 11th. Finally, TheStreet raised shares of Genomic Health from a “c” rating to a “b-” rating in a report on Friday, August 3rd. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $45.44.

Shares of Genomic Health stock traded up $1.11 on Tuesday, hitting $62.28. 308,000 shares of the company’s stock traded hands, compared to its average volume of 254,496. The stock has a market capitalization of $2.19 billion, a price-to-earnings ratio of 6,228.00 and a beta of 0.44. Genomic Health has a one year low of $26.54 and a one year high of $62.47.

In other news, insider Steven Shak sold 5,500 shares of the business’s stock in a transaction on Monday, June 11th. The shares were sold at an average price of $50.22, for a total value of $276,210.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Fred E. Cohen sold 8,250 shares of the company’s stock in a transaction on Tuesday, August 7th. The stock was sold at an average price of $56.22, for a total transaction of $463,815.00. Following the completion of the transaction, the director now directly owns 75,572 shares of the company’s stock, valued at $4,248,657.84. The disclosure for this sale can be found here. Insiders sold a total of 113,279 shares of company stock valued at $5,974,932 in the last three months. 45.80% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. BlackRock Inc. boosted its stake in Genomic Health by 3.6% in the 2nd quarter. BlackRock Inc. now owns 2,002,972 shares of the medical research company’s stock worth $100,949,000 after purchasing an additional 68,691 shares during the period. Millennium Management LLC boosted its stake in Genomic Health by 114.0% in the 2nd quarter. Millennium Management LLC now owns 1,446,250 shares of the medical research company’s stock worth $72,891,000 after purchasing an additional 770,413 shares during the period. Renaissance Technologies LLC boosted its stake in Genomic Health by 18.8% in the 2nd quarter. Renaissance Technologies LLC now owns 1,404,924 shares of the medical research company’s stock worth $70,808,000 after purchasing an additional 222,324 shares during the period. Point72 Asset Management L.P. boosted its stake in Genomic Health by 136.0% in the 1st quarter. Point72 Asset Management L.P. now owns 388,400 shares of the medical research company’s stock worth $12,153,000 after purchasing an additional 223,800 shares during the period. Finally, Northern Trust Corp boosted its stake in Genomic Health by 0.6% in the 1st quarter. Northern Trust Corp now owns 269,424 shares of the medical research company’s stock worth $8,430,000 after purchasing an additional 1,608 shares during the period. 89.33% of the stock is owned by hedge funds and other institutional investors.

About Genomic Health

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

Recommended Story: Asset Allocation, Balancing Your Investments

Get a free copy of the Zacks research report on Genomic Health (GHDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.